Exactly right OE, and that development is both expensive and very risky. Indeed, most potential pharmaceutical products never make it through trials, never make it to market. The industry writes off billions of dollars along the way. Those expenses need to be recovered and the risk needs to be compensated through adequate pricing of the products that are successful.
CSL possible pull back to low $200's, page-76
-
- There are more pages in this discussion • 507 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$306.60 |
Change
4.560(1.51%) |
Mkt cap ! $148.1B | |||
| Open | High | Low | Value | Volume |
| $303.41 | $306.68 | $303.01 | $215.1M | 707.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3499 | $306.60 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $306.68 | 284 | 2 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |